Physician profile
Daragh Heitzman
NPI 1023083961
$27,328.39
in general payments reported to CMS, 2019-2025
67 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $641 · 2021: $3,721 · 2022: $3,604 · 2023: $12K · 2024: $3,443 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,588 · Food and Beverage: $7,931 · Travel and Lodging: $902 · Education: $10.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,587.50 |
| Food and Beverage | $7,931.12 |
| Travel and Lodging | $901.98 |
| Education | $10.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $10,336.51 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $3,605.12 | 2019-2022 | |
| Abbvie INC. | $1,211.33 | 2019-2025 | |
| Genentech USA, INC. | $929.71 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Ucb, INC. | $813.50 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Biogen, INC. | $710.65 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Alexion Pharmaceuticals, INC. | $659.24 | 2019-2024 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $580.93 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $574.07 | 2022-2025 | Ajovy, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $534.18 | 2019-2025 | |
| Argenx US, INC. | $516.33 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $474.00 | 2019-2025 | |
| Lilly USA, LLC | $443.06 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Celgene Corporation | $401.34 | 2022-2025 | Zeposia |
| Genzyme Corporation | $324.88 | 2019-2024 |
Show all 61 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,600,758.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daragh Heitzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.